Francis Bacon painting sells for record $142.4 million in New York

November 13, 2013

Francis_Bacon

New York, Nov 13: Francis Bacon's three-paneled painting " Three Studies of Lucian Freud" became the most expensive work of art ever sold at auction on Tuesday when it soared to $142.4 million at Christie's.

The 1969 triptych, never before offered at auction and which carried a pre-sale estimate of about $85 million, easily eclipsed the $119.9 million price of Edvard Munch's "The Scream," achieved in May of last year at Sotheby's. The previous record for a Bacon work of art was $86.3 million set in 2008.

The monumental painting depicts the Dublin-born painter's friend and fellow artist Lucian Freud on a chair, with a view from each side and one face-on. Christie's called it "a true masterpiece that marks Bacon and Freud's relationship" and their "creative and emotional kinship."

With bidding starting at a whopping $80 million, it sold after a protracted bidding war both in the packed New York salesroom and via telephone. Christie's did not disclose the identity of the successful buyer.

"Three Studies of Lucian Freud" is also one of only two existing full-length triptychs of Freud, a grandson of the founder of psychoanalysis Sigmund Freud, and the three panels were separated for 15 years in the 1970s before being reunited, Christie's said.

The auction also set another significant record, for a price achieved at auction by any living artist, when Jeff Koons's large sculpture, "Balloon Dog (Orange)," fetched $58.4 million, beating the high pre-sale estimate and smashing the old mark for a living artist of $37.1 million set by Gerhard Richter's "Domplatz, Mailand (Cathedral Square, Milan)" earlier this year.

Auction officials have said that new, deep-pocketed collectors from around the globe are driving prices for top-tier works to record levels.

At a recent preview, Christie's head of postwar and contemporary art, Brett Gorvy, noted that collectors from Asia, Russia and the Mideast flush with cash were determined to assemble world-class collections featuring trophy works.

Comments

Skadze wszystek sposród nas planuje operowac sytuowanie
jednostki w google obok poszczególnego kapitalisci Czyniac w znaczacych firmach niby równiez w nizszych nazwach znacznie nieraz jestesmy
zwodzeni jakze takze zajmowani na jakims Sposród frazeologizmem przedstawiamy ostatniego
któregokolwiek niezwlocznie dostatecznie

Also visit my homepage: pozycjonowanie stron: http://www.bjhomespa.com/comment/html/?1287.html

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

COVID-19 may soon be cured; Japanese pharma says creating drugs

News Network

March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments